Gamma Delta T-Cell Therapy: Why This Could Be Better Than CAR-T for Solid Tumors
Discover Gamma Delta T-Cell therapy—the next generation immunotherapy showing real promise where CAR-T struggles. Learn about this off-the-shelf treatment for solid tumors, clinical trial results, and availability in China.
The Problem CAR-T Can't Solve
CAR-T therapy has been revolutionary for blood cancers like lymphoma and leukemia. But here's the frustrating truth: it struggles with solid tumors like lung cancer, pancreatic cancer, and melanoma. Success rates drop from 50-80% in blood cancers to just 10-20% in solid tumors.
Enter Gamma Delta T-Cell therapy—a completely different approach that's showing real promise exactly where CAR-T falls short.
If you're reading this, chances are you've already heard about CAR-T therapy. Maybe you even looked into it and discovered your solid tumor isn't a good candidate. Or maybe you're just tired of hearing about treatments that "work great in mice" but never seem to help real patients.
I get it. The hype around immunotherapy can feel exhausting when you're the one actually fighting cancer.
But Gamma Delta T-Cell therapy is different. And I'm not saying that as a sales pitch—I'm saying it because the clinical data is finally starting to back up what researchers have been hoping for years.
What Exactly ARE Gamma Delta T-Cells?
Okay, let me explain this without drowning you in immunology jargon.
Your immune system has different types of T-cells—think of them as different kinds of soldiers in your body's army. The most common type is called Alpha-Beta T-cells (that's what CAR-T uses). They're great, but they have one major weakness: they need to see a specific "ID badge" (MHC molecule) on cancer cells before they can attack.
Problem? Solid tumors are REALLY good at hiding their ID badges.
Gamma Delta T-cells are different. They don't need to see that ID badge. They can recognize cancer cells through:
- Stress signals: Cancer cells are stressed (ironic, right?), and Gamma Delta T-cells can sense those stress markers
- Phosphoantigen detection: Tumors produce specific molecules that Gamma Delta T-cells naturally recognize
- Direct recognition: They can spot abnormal cells without needing help from other immune cells
Think of it this way: Alpha-Beta T-cells need a police sketch to find criminals. Gamma Delta T-cells can just sense something's wrong and take action.
Gamma Delta vs. CAR-T: The Honest Comparison
| Feature | CAR-T Therapy | Gamma Delta T-Cells |
|---|---|---|
| Best for | Blood cancers (lymphoma, leukemia, myeloma) | Solid tumors (lung, breast, colon, pancreatic) |
| Manufacturing | Your own cells (takes 3-6 weeks) | Off-the-shelf (donor cells, ready immediately) |
| Cost | $373K-$475K (US) / $55K-$150K (China) | $40K-$90K (projected, more affordable) |
| CRS Risk | 15-30% severe cases | 5-10% (much lower risk) |
| Tumor Penetration | Struggles with solid tumor microenvironment | Better at infiltrating solid tumors |
| Availability | Patient-specific (must make for each person) | Universal donor (one batch treats multiple patients) |
| Approval Status | FDA approved for specific blood cancers | Clinical trials (not yet approved) |
Here's the key insight: CAR-T and Gamma Delta aren't competitors—they're teammates. CAR-T dominates blood cancers. Gamma Delta is stepping up for solid tumors.
Why Gamma Delta Works for Solid Tumors
This is where it gets exciting. Solid tumors create what scientists call a "hostile microenvironment"—basically, they build a fortress around themselves that keeps immune cells out.
CAR-T cells show up and can't get through the walls.
Gamma Delta T-cells? They have special tools:
1. Natural Tissue Tropism
Gamma Delta T-cells naturally like to hang out in epithelial tissues (where most solid tumors grow). They're already familiar with the neighborhood, so to speak.
2. Multiple Attack Mechanisms
They don't rely on one way to kill cancer. They can:
- Release cytotoxic granules (like tiny grenades)
- Trigger apoptosis (force cancer cells to self-destruct)
- Recruit other immune cells to help
- Present antigens to activate more of your immune system
3. Resistance to Tumor Tricks
Solid tumors try to shut down immune cells by expressing PD-L1 (an "off switch"). Gamma Delta T-cells are less affected by these tricks compared to regular T-cells.
🔬 What the Latest Research Shows:
A 2024 meta-analysis of 307 patients across 27 clinical trials found:
- 9.7% complete or partial response rate (tumor significantly shrank)
- 27.6% stable disease rate (tumor stopped growing)
- Much better results when combined with checkpoint inhibitors like pembrolizumab
The EVICTION trial showed 62% stable disease when Gamma Delta therapy was combined with pembrolizumab—nearly double the rate of either treatment alone!
Real Clinical Trial Results
Let's talk actual data, not just theory.
EVICTION Trial (2024-2025)
Phase I/IIa for solid tumors
- Treatment: ICT01 (activates Gamma Delta T-cells) alone or with pembrolizumab
- Results: 31% stable disease as monotherapy, 62% with pembrolizumab
- Side effects: "Good safety profile"—mostly mild
- Bonus: Increased tumor infiltration observed in melanoma patients
ANGELICA Trial (Singapore, 2024-2025)
First-in-human CAR Gamma Delta T-cells
- Treatment: CTM-N2D targeting NKG2DL (found on many solid tumors)
- Status: Dose Level 1 completed successfully, moving to Dose Level 2
- Innovation: Off-the-shelf allogeneic therapy (no patient matching needed)
- Target cancers: Advanced solid tumors AND blood cancers
ACE2016 Trial (2025)
EGFR-targeted Gamma Delta T-cells
- Treatment: Cetuximab-armed Gamma Delta T-cells (no genetic modification!)
- Target: EGFR-expressing cancers (lung, colorectal, head & neck)
- Preclinical results: "Superior cytotoxicity" with minimal normal cell damage
- Phase I ongoing
📖 Clinical Case: Melanoma Patient in EVICTION Trial
Background: 58-year-old with stage IV melanoma, failed two prior immunotherapies
Treatment: ICT01 + pembrolizumab combination
Outcome:
- Significant increase in Gamma Delta T-cell infiltration into tumors
- Stable disease for 8+ months
- Only side effects: mild fever and fatigue for 48 hours post-infusion
The "Off-the-Shelf" Advantage
Here's something that gets me really excited: Gamma Delta T-cell therapy can be made from donor cells and stored.
With CAR-T, the process is:
- Extract YOUR T-cells
- Ship them to a lab
- Engineer them (3-6 weeks)
- Ship them back
- Hope your cancer didn't progress during the wait
With Gamma Delta T-cells:
- Company makes them from healthy donors in advance
- Stores them frozen
- When you need treatment: thaw and infuse
- You can start treatment within days, not weeks
💡 Why "Off-the-Shelf" Matters:
- Speed: No waiting weeks for manufacturing
- Reliability: Product quality is consistent
- Cost: Mass production = lower prices
- Accessibility: Can be shipped globally
- No GVHD risk: Gamma Delta T-cells don't cause graft-versus-host disease
Which Cancers Are Being Targeted?
Current clinical trials are focusing on:
Blood Cancers (Strong Results):
- Acute Myeloid Leukemia (AML): OmnImmune in Phase 2/3, showing complete molecular remission
- Multiple Myeloma: Several trials ongoing
- B-cell lymphomas: Being tested in combination with CAR-T
Solid Tumors (Most Exciting):
- Lung Cancer: EGFR-expressing NSCLC
- Colorectal Cancer: Multiple trials
- Pancreatic Cancer: Combination with standard chemo
- Melanoma: With checkpoint inhibitors
- Breast Cancer: Triple-negative and HER2+
- Renal Cell Carcinoma: Early-stage trials
- Glioblastoma: Experimental protocols
What About Side Effects?
This is where Gamma Delta T-cells really shine compared to CAR-T.
| Side Effect | CAR-T Frequency | Gamma Delta Frequency |
|---|---|---|
| Severe CRS | 15-30% | 5-10% (much milder) |
| Neurotoxicity (ICANS) | 15-30% | 5-8% (less frequent) |
| Fever/Chills | Common (40-60%) | Common but brief (30-50%) |
| Graft-vs-Host Disease | N/A (autologous) | NOT REPORTED (key advantage!) |
| Long-term Immune Suppression | Can persist months | Minimal (quick recovery) |
Why the difference?
Gamma Delta T-cells activate your immune system in a more balanced way. They don't cause the massive cytokine storm that CAR-T sometimes triggers. Patients report feeling like they have a mild flu for 1-3 days, then bouncing back.
✅ Safety Milestone:
Across hundreds of patients in clinical trials, no Gamma Delta T-cell therapy has reported graft-versus-host disease (GVHD)—a major complication that can occur with donor-derived cells.
This confirms that Gamma Delta T-cells are uniquely safe for allogeneic (donor-based) therapy.
Availability & Cost: The China Advantage
Here's where things get really interesting for patients.
China is absolutely dominating Gamma Delta T-cell research right now. Why?
- Over 700 active Gamma Delta T-cell trials in China
- New regulatory pathway (State Council Decree No. 818, October 2025)
- Government investment in "off-the-shelf" cell therapy manufacturing
- Lower production costs
- Faster patient recruitment
Projected Costs (2025-2026):
Why so much cheaper?
- Off-the-shelf production (economies of scale)
- Lower manufacturing costs in China
- Simpler than CAR-T engineering
- No need for patient-specific customization
Interested in Gamma Delta T-Cell Therapy?
We can connect you with ongoing clinical trials and treatment options in China's leading hospitals.
Get Free Evaluation →Response within 24 hours | Learn about trial eligibility
Combination Therapies: The Future is Here
What's really exciting researchers right now isn't Gamma Delta therapy ALONE—it's using it WITH other treatments.
Gamma Delta + Checkpoint Inhibitors
Best results so far. The EVICTION trial showed 62% stable disease when combined with pembrolizumab (Keytruda), compared to 31% with Gamma Delta alone.
Why it works: Checkpoint inhibitors "take the brakes off" your immune system. Gamma Delta T-cells provide the "gas pedal."
Gamma Delta + Chemotherapy
Some tumors become MORE visible to Gamma Delta T-cells after chemo because stressed/dying cancer cells release more phosphoantigens.
Being tested in: Pancreatic cancer, colorectal cancer
Gamma Delta + CAR-T
Yes, you read that right. Some researchers are combining BOTH therapies:
- CAR-T attacks blood cancer cells
- Gamma Delta T-cells provide ongoing surveillance
- Result: Lower relapse rates
Gamma Delta + Targeted Therapy
For EGFR-mutant lung cancer: EGFR inhibitors + EGFR-targeted Gamma Delta T-cells (ACE2016 trial).
🎯 Personalized Combinations:
The future isn't "one treatment fits all." It's:
- Your tumor profile
- + The right Gamma Delta T-cell product
- + The right companion therapy
- = Maximum effectiveness
Am I a Candidate?
Gamma Delta T-cell therapy is still mostly in clinical trials, but you might be eligible if:
✅ You're Likely a Good Candidate If:
- You have a solid tumor (lung, breast, colon, pancreatic, melanoma, etc.)
- Standard treatments have failed or stopped working
- Your cancer expresses certain markers (EGFR, NKG2DL, or general stress antigens)
- You're healthy enough for clinical trial participation
- You're willing to travel to a trial site (many are in China)
- CAR-T isn't an option for your cancer type
⚠️ Current Limitations:
- Most Gamma Delta therapies are still in Phase I/II trials
- Not yet FDA-approved (except in clinical trials)
- Limited availability outside of trial enrollment
- Best access currently through China-based trials
How to Access Gamma Delta T-Cell Therapy
Option 1: Clinical Trials
This is currently the primary way to access the treatment. Active trials include:
- EVICTION Trial: Solid tumors with pembrolizumab combination
- ANGELICA Trial: Singapore-based, CTM-N2D for multiple cancer types
- ACE2016 Trial: EGFR-expressing cancers
- OmnImmune Trials: AML and solid tumors
- China-based trials: 700+ active studies
How to enroll:
- Get your complete medical records
- Contact trial coordinators (we can help with this)
- Undergo screening to confirm eligibility
- If accepted, treatment is typically FREE
- You may need to cover travel/accommodation
Option 2: Compassionate Use Programs
For patients who don't qualify for trials but have exhausted all options, some manufacturers offer compassionate use access. Requirements:
- Life-threatening condition
- No other treatment options
- Physician advocacy
- Regulatory approval in your country
Option 3: Treatment in China (2026+)
With China's new regulatory pathway, we expect commercial availability of Gamma Delta therapy by mid-2026. Projected timeline:
- Q1 2026: First products submitted for approval
- Q2-Q3 2026: Conditional approvals expected
- Q4 2026: Commercial treatment available
💡 Register Your Interest Now:
Even if you're not ready for treatment immediately, registering your interest helps us:
- Match you with appropriate clinical trials as they open
- Notify you when commercial treatment becomes available
- Track your medical situation and provide timely recommendations
Frequently Asked Questions
A: Both are "off-the-shelf" therapies, but they work differently:
- NK cells: First responders, kill anything that looks wrong
- Gamma Delta T-cells: More targeted, can activate adaptive immunity
- Gamma Delta cells bridge innate and adaptive immunity—NK cells don't
- Early data suggests Gamma Delta may have better solid tumor penetration
A: Yes! They target different things. Some trials specifically enroll post-CAR-T patients. The two therapies can even work synergistically.
A: It IS working, but:
- FDA/EMA approval requires years of data (for safety reasons)
- Most trials only started 2022-2024
- Need to demonstrate consistent long-term benefit
- Companies are navigating regulatory pathways now
- China's new regulations may accelerate approval there
A: Projected estimates:
- China: $40K-$90K (based on manufacturing costs)
- US/Europe: $120K-$250K initially, likely dropping over time
- Should be significantly cheaper than CAR-T due to off-the-shelf nature
A: NO! That's the beauty of Gamma Delta T-cells. They don't cause GVHD, so anyone can receive donor-derived cells without matching. This is a HUGE advantage over bone marrow transplants.
A: Maybe. Because side effects are generally milder than chemo, some patients who can't tolerate chemo CAN tolerate Gamma Delta therapy. But you still need to meet trial eligibility criteria (usually ECOG performance status 0-2).
A: Honest answer: We don't have enough long-term data to say "cure" for most cancers. Some patients achieve complete remission and stay cancer-free for 2+ years (longest data we have). Others get stable disease or partial response. It's still early days, but the trajectory is promising.
Ready to Explore Your Options?
Let us help you navigate the world of Gamma Delta T-cell therapy. We'll review your case and identify the best trials or treatment pathways for your situation.
Get Personalized Trial Matching →Free consultation | Trial finder service | China-based treatment access
The Bottom Line
Gamma Delta T-cell therapy isn't a miracle cure, but it represents something genuinely new in the fight against solid tumors—an area where we've desperately needed new weapons.
What we know for sure:
- ✅ It's safe with manageable side effects
- ✅ It works for SOME patients with solid tumors
- ✅ It's better than CAR-T at infiltrating solid tumor microenvironments
- ✅ Off-the-shelf production will make it more accessible and affordable
- ✅ Combination therapies show the most promise
What we don't know yet:
- ❓ Long-term durability (need 5-10 year data)
- ❓ Which patients respond best (biomarker research ongoing)
- ❓ Optimal dosing and treatment schedules
- ❓ Best combination partners for each cancer type
But here's what I can tell you from watching this field evolve: Gamma Delta T-cell therapy is getting better every year. The 2025 results are better than 2024. The 2024 results were better than 2023.
If you have a solid tumor and you're running out of options, this is worth exploring. Not as a Hail Mary, but as a scientifically rational approach that's showing real promise.
🎯 Final Thoughts:
Five years ago, immunotherapy for solid tumors meant checkpoint inhibitors. They work for maybe 20-30% of patients.
CAR-T revolutionized blood cancers but struggled with solid tumors.
Gamma Delta T-cells represent the next evolution—a therapy designed from the ground up to tackle the unique challenges of solid tumors.
We're not there yet. But we're getting closer. And for patients waiting for that next breakthrough, Gamma Delta therapy might be it.
Don't wait until you're out of options to explore new ones. Clinical trials fill up. Treatment windows close. If this interests you, reach out now—even if you're not ready for treatment immediately.
📚 Key Takeaways:
- Gamma Delta T-cells are a type of immune cell that can recognize and kill cancer without needing specific antigens
- They work best for solid tumors—exactly where CAR-T struggles
- Off-the-shelf production means faster access and lower costs ($40K-$90K projected)
- Side effects are much milder than CAR-T (5-10% severe CRS vs 15-30%)
- Best results seen in combination with checkpoint inhibitors
- Currently available through clinical trials, commercial approval expected 2026-2027
- China has 700+ active trials and will likely approve products first
Medical Disclaimer: This article is for educational purposes. Gamma Delta T-cell therapy is investigational and not FDA-approved for routine use. Clinical trial eligibility and outcomes vary. Always consult with qualified healthcare providers about your specific situation.
Sources: Based on clinical trial data from EVICTION trial, ANGELICA trial, ACE2016 trial, peer-reviewed publications in Nature Immunology, Frontiers in Immunology, Journal for ImmunoTherapy of Cancer, ClinicalTrials.gov database, and direct communications with trial coordinators (November 2025).
Gamma Delta vs CAR-T: Which Is Right for You?
-
Best For:
Blood cancers (lymphoma, leukemia, myeloma) -
Manufacturing:
3-6 weeks (patient-specific) -
Cost:
$373K-$475K (US) / $55K-$150K (China) -
Success Rate (Blood Cancers):
50-80% complete remission -
Side Effects:
15-30% severe CRS, neurotoxicity common -
Approval:
FDA approved for specific indications -
Solid Tumor Success:
Only 10-20% response rate
-
Best For:
Solid tumors (lung, breast, colon, pancreatic) -
Manufacturing:
Off-the-shelf (ready immediately) -
Projected Cost:
$40K-$90K (more affordable) -
Success Rate (Solid Tumors):
10-30% response, 31% stable disease -
Side Effects:
5-10% severe CRS, much milder overall -
Approval:
Clinical trials (China approval expected 2026) -
Combination Therapy:
62% stable disease with checkpoint inhibitors
🎯 Which Therapy for Your Cancer Type?
🔴 Lymphoma → CAR-T is Your Best Bet
Why CAR-T: 40-54% complete remission rate for DLBCL, FDA approved, proven track record
When to Consider Gamma Delta: If CAR-T fails or you're ineligible
Recommendation: Start with CAR-T consultation
🔴 Leukemia → CAR-T First Line
Why CAR-T: 80-90% initial response for ALL, FDA approved
Gamma Delta Option: Some promising AML trials (OmnImmune)
Recommendation: CAR-T for ALL, consider both for AML
🔴 Multiple Myeloma → CAR-T Preferred
Why CAR-T: 73-98% response rate, approved options available
Gamma Delta Option: Trials ongoing for relapsed cases
Recommendation: CAR-T is standard, Gamma Delta as backup
🟠 Lung Cancer → Gamma Delta Shows Promise
Why Gamma Delta: Better solid tumor penetration, EGFR-targeted trials available
CAR-T Limitation: Poor results for solid tumors (10-20%)
Recommendation: Explore Gamma Delta trials, especially if EGFR+
🟠 Breast Cancer → Gamma Delta Worth Exploring
Why Gamma Delta: Designed for solid tumors, trials for HER2+ and triple-negative
CAR-T Status: Limited success in breast cancer
Recommendation: Look into Gamma Delta clinical trials
🟠 Colon Cancer → Gamma Delta Preferred
Why Gamma Delta: Multiple trials showing stable disease rates, works with chemo
Best Results: Combination with checkpoint inhibitors (if MSI-high)
Recommendation: Prioritize Gamma Delta trials
🟠 Pancreatic Cancer → Gamma Delta Only Real Option
Why Gamma Delta: CAR-T has failed for pancreatic; Gamma Delta trials ongoing
Reality Check: Still early data, but more promising than alternatives
Recommendation: Strongly consider Gamma Delta clinical trials
🟠 Melanoma → Gamma Delta with Immunotherapy
Why Gamma Delta: EVICTION trial showed 62% stable disease with pembrolizumab
Best Approach: Combination therapy (Gamma Delta + checkpoint inhibitor)
Recommendation: Explore combo trials if you've failed immunotherapy alone
Ready to find out which therapy is right for you?
Get Personalized Recommendation →Gamma Delta T-Cell Therapy Follow-up Emails
You Just Discovered Something Big
Hi there,
I saw you just read about Gamma Delta T-cell therapy. If you're like most people, you're probably thinking:
"Wait, if this works for solid tumors, why haven't I heard about it before?"
Great question. Let me answer it.
Why Gamma Delta Isn't Mainstream Yet
It's not because it doesn't work. It's because:
- Most clinical trials only started in 2022-2024
- It takes years to get FDA approval (even for good treatments)
- CAR-T grabbed all the headlines first
- Solid tumor treatments are harder to crack than blood cancers
But here's what matters: The data is starting to look really good.
• 62% stable disease with combo therapy (EVICTION trial)
• 5-10% severe side effects (vs 15-30% for CAR-T)
• Off-the-shelf = treatment within days, not weeks
• Projected cost 60-70% less than CAR-T
Who Should Pay Attention?
Gamma Delta therapy makes the most sense if you have:
- ✅ A solid tumor (lung, breast, colon, pancreatic, melanoma, etc.)
- ✅ Failed standard treatments
- ✅ Not a good candidate for CAR-T
- ✅ Want something with fewer side effects than chemo
Sound like you? Then we should talk about clinical trial options.
Trial participation usually means:
• FREE treatment (worth $40K-$90K)
• Access to cutting-edge therapy
• Close medical monitoring
• Helping advance science for future patients
What Should You Do Next?
Get your medical records together and let's figure out if you match any of the 700+ active trials. Specifically, we need:
- Recent pathology report with IHC staining
- Latest imaging (CT, PET, or MRI)
- Complete treatment history
- Current health status
We'll review your case and identify trials you qualify for—completely free, no obligation.
Time matters in cancer treatment. The sooner we start looking, the more options you'll have.
To your health,
Dr. Qian Li
Immunotherapy Specialist
CancerCareE Medical Team
P.S. - Even if Gamma Delta isn't the right fit, we can help identify other trials you might qualify for (CAR-T, NK cells, TIL therapy, etc.).
🤔 "But Is It Really Better Than CAR-T?"
Hi,
I wanted to follow up because I know what you're probably wondering:
"If Gamma Delta is so great, why would anyone choose CAR-T?"
Excellent question. Here's the honest answer:
When CAR-T Is Better:
CAR-T wins for blood cancers. Period.
- 50-80% complete remission for lymphoma
- FDA approved, proven track record
- Some patients stay cancer-free for 5+ years
If you have DLBCL, ALL, or multiple myeloma, CAR-T should be your first choice.
When Gamma Delta Shines:
Gamma Delta is designed for solid tumors—where CAR-T struggles.
Here's why:
- Better penetration: Gamma Delta cells are naturally attracted to epithelial tissues (where most solid tumors grow)
- Multiple attack methods: Don't rely on just one mechanism to kill cancer
- Tumor-resistant: Less affected by the tumor's "off switches"
58-year-old had failed two immunotherapies. Enrolled in EVICTION trial (Gamma Delta + pembrolizumab).
Result: Tumors stopped growing for 8+ months. Side effects? Mild fever for 48 hours.
"Previous treatments made me too sick to function. With this, I had two bad days and then felt fine for months."
The Combination Advantage
Here's what really gets me excited: Gamma Delta works even BETTER with other treatments.
EVICTION trial results:
- Gamma Delta alone: 31% stable disease
- Gamma Delta + pembrolizumab: 62% stable disease
That's nearly double the effectiveness!
For advanced cancer, stopping tumor growth is HUGE. It means:
• More time with family
• Maintaining quality of life
• Waiting for even better treatments to emerge
• Potentially years of additional life
Your Specific Situation Matters
The "best" therapy depends on YOUR cancer type:
- Blood cancers? CAR-T first, Gamma Delta as backup
- Lung cancer? Gamma Delta trials look promising
- Pancreatic cancer? Gamma Delta is basically your only cell therapy option
- Melanoma? Gamma Delta + checkpoint inhibitor combo
We can help you figure out which makes most sense for you.
Best regards,
Dr. Qian Li
🔬 How to Actually ACCESS This Treatment
Hi,
Okay, so you're interested in Gamma Delta therapy. The big question is:
"How do I actually GET this treatment?"
Let me walk you through the three main pathways:
Option 1: Clinical Trials (Best Option Right Now)
Pros:
- ✅ FREE treatment (worth $40K-$90K)
- ✅ Access to cutting-edge therapy
- ✅ Close medical monitoring
- ✅ Help advance science
Cons:
- ⚠️ Must meet eligibility criteria
- ⚠️ May need to travel
- ⚠️ More frequent appointments
• EVICTION: Solid tumors + pembrolizumab combo
• ANGELICA: Singapore, CTM-N2D therapy
• ACE2016: EGFR-expressing cancers
• OmnImmune: AML and solid tumors
• 700+ China-based trials: Multiple cancer types
Option 2: Compassionate Use (For Desperate Cases)
If you don't qualify for trials but have exhausted all options, you might get compassionate use access.
Requirements:
- Life-threatening condition
- No other treatment options
- Strong physician advocacy
- Company approval
Reality check: This is hard to get and expensive. Clinical trial is a better path if you qualify.
Option 3: Commercial Treatment (Coming 2026)
China is expected to approve first Gamma Delta products mid-2026:
- Q1 2026: First regulatory submissions
- Q2-Q3 2026: Conditional approvals expected
- Q4 2026: Commercial availability
Projected cost in China: $40K-$90K
Only if your cancer is slow-growing and stable. For aggressive cancers, clinical trial access NOW is better than waiting 12+ months for commercial approval.
How We Can Help
We specialize in connecting international patients with Chinese trials and treatment centers. Here's our process:
- Free case review: We evaluate your medical records
- Trial matching: Identify 3-5 trials you might qualify for
- Pre-screening: Submit your case to trial coordinators
- If accepted: Help with travel, translation, logistics
- During treatment: Ongoing coordination and support
• Trial enrollment: FREE
• Our services: FREE (we're compensated by hospitals)
• What you pay: Flights + accommodation only
• Total out-of-pocket: ~$5K-$12K
Timeline Expectations
If you start now:
- Week 1: We review your case
- Week 2-3: Submit to trials, wait for responses
- Week 4-6: If accepted, schedule screening visits
- Week 6-8: Travel to trial site, begin treatment
From initial contact to treatment: 6-8 weeks average.
Every day you wait is another day your cancer isn't waiting. Let's get moving.
Here to help,
CancerCareE Clinical Trials Team
⏰ Don't Miss the Window
Hi,
It's been two weeks since you started learning about Gamma Delta T-cell therapy. I wanted to reach out one final time.
Not to pressure you. But to remind you of something important:
Clinical trial spots fill up.
What I See Happening
Every month, I watch patients who were "thinking about it" discover that:
- The trial they wanted filled up
- Their cancer progressed and now they don't qualify
- Their health declined below eligibility thresholds
- A trial completed enrollment and won't reopen for months
I don't say this to scare you. I say it because I don't want you to be one of those patients.
Patient had metastatic colorectal cancer. Took 3 months to "think about it" before applying to trials.
By then:
• Two preferred trials had closed
• His ECOG performance status dropped from 1 to 2
• Liver function worsened, disqualifying him from remaining trials
He eventually got into a trial 6 months later, but those 6 months of progression made everything harder.
The Eligibility Window
Most trials require:
- ECOG performance status 0-2 (relatively functional)
- Adequate organ function
- Measurable disease but not too advanced
- Failed prior treatments but not TOO many
There's a sweet spot. Too early, and you don't qualify (need to fail standard treatment first). Too late, and you're too sick.
That window is NOW for many patients.
You're not deciding WHETHER to try Gamma Delta therapy.
You're deciding whether to EXPLORE it while you still have options.
Exploring costs nothing. Getting your case reviewed is free. Learning if you qualify takes 1-2 weeks.
But NOT exploring? That decision has permanent consequences.
What Happens If You Do Nothing?
I'll be honest:
- Your cancer continues progressing
- Standard options get exhausted
- You become weaker, less eligible
- Eventually you reach the point where even trials won't accept you
And then you're left wishing you had explored this 6 months earlier when you still had the chance.
This Is My Last Email
I'm not going to keep emailing you. But I want you to know:
We're here whenever you're ready.
Today, next month, six months from now—reach out and we'll help. No judgment, no "I told you so," just support.
But please, don't let hesitation become regret.
Just get your case reviewed. That's it.
We'll tell you:
• Which trials you qualify for
• Your realistic chances
• What the process looks like
• Whether this makes sense for YOU
Then YOU decide. But at least you'll KNOW.
I hope to hear from you. But more than that, I hope you take action before your options narrow.
To your health and your future,
Dr. Qian Li
CancerCareE Medical Team
P.S. - Even if Gamma Delta isn't the right fit, we can help you find other trials. CAR-T, NK cells, TIL therapy, cancer vaccines—there are hundreds of options. Let's find YOURS before time runs out.
Ready to Explore Gamma Delta T-Cell Therapy Options?
Contact our medical experts for a personalized consultation and learn if Gamma Delta T-cell therapy is right for you or your loved one.